argenx SE (LON:0QW0)

London flag London · Delayed Price · Currency is GBP · Price in EUR
474.48
-2.87 (-0.60%)
At close: Jul 1, 2025
17.78%
Market Cap 24.21B
Revenue (ttm) 2.05B
Net Income (ttm) 823.61M
Shares Out n/a
EPS (ttm) 12.34
PE Ratio 29.40
Forward PE 35.05
Dividend n/a
Ex-Dividend Date n/a
Volume 7,688
Average Volume 7,026
Open 469.05
Previous Close 477.35
Day's Range 466.50 - 478.00
52-Week Range 398.50 - 656.80
Beta 0.04
RSI 33.50
Earnings Date Jul 31, 2025

About argenx SE

argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYGART and VYGART HYTRULO to treat generalized myasthenia gravis (gMG), immune thrombocytopenia (ITP), and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative and ocular gMG, thyroid eye diseases, ITP, myositis, Sjögren’s disease, lupus nephropathy, systemic sclerosis, ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2008
Employees 1,599
Stock Exchange London Stock Exchange
Ticker Symbol 0QW0
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements

News

There is no news available yet.